Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDRadiopharm Theranostics Ltd Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$0.01 | -$0.01 | -$0.01 |
Radiopharm Theranostics Ltd Earnings Date And Information
Radiopharm Theranostics Ltd last posted its earnings results on Friday, August 28th, 2026. The company reported $-1.19572 earnings per share for the quarter, topping analysts' consensus estimates of $-1.67091 by $0.47519. The company had revenue of 1.40 M for the quarter and had revenue of 2.71 M for the year. Radiopharm Theranostics Ltd has generated $-5 earnings per share over the last year ($-4.56 diluted earnings per share) and currently has a price-to-earnings ratio of -0.51. Radiopharm Theranostics Ltd has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Radiopharm Theranostics Ltd Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/28/2026 | Q4 2025 | -$1.67 | -$729.00 | -727.33 | $921.70 K | $1.40 M |
| 02/27/2026 | Q2 2025 | N/A | -$675.00 | N/A | $972.27 K | $1.36 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Radiopharm Theranostics Ltd Earnings: FAQ's
In the previous quarter, Radiopharm Theranostics Ltd (:RADX) reported $-1.19572 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.67091 by $0.47519.
The conference call for Radiopharm Theranostics Ltd's latest earnings report can be listened to online.
The conference call transcript for Radiopharm Theranostics Ltd's latest earnings report can be read online.
Radiopharm Theranostics Ltd (:RADX) has a recorded annual revenue of $2.71 M.
Radiopharm Theranostics Ltd (:RADX) has a recorded net income of $-53,944,069.Radiopharm Theranostics Ltd has generated $-4.56 earnings per share over the last four quarters.
Radiopharm Theranostics Ltd (:RADX) has a price-to-earnings ratio of -0.51 and price/earnings-to-growth ratio is -0.01.